טוען...
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies
Vancomycin-resistant enterococci (VRE) are a leading cause of nosocomial infections due to the limited number of effective therapeutic options. In an effort to repurpose FDA-approved drugs against antibiotic-resistant bacteria, we identified auranofin as a potent drug against VRE. The present study...
שמור ב:
| הוצא לאור ב: | Int J Antimicrob Agents |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7073294/ https://ncbi.nlm.nih.gov/pubmed/31669742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijantimicag.2019.10.009 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|